Biomarkers in medicine最新文献_第4页

Admission blood glucose and neutrophil-to-lymphocyte ratio for differentiating CT-positive from CT-negative mild traumatic brain injury. 入院血糖和中性粒细胞/淋巴细胞比值鉴别ct阳性与阴性轻度颅脑损伤。

IF 2.1 4区医学

Biomarkers in medicine Pub Date : 2026-01-01 Epub Date: 2026-01-13 DOI: 10.1080/17520363.2026.2615618

Marios Lampros, George A Alexiou, Solonas Symeou, Lamprini Vlachodimitropoulou, Aikaterini Zerva, Spyridon Voulgaris

{"title":"Admission blood glucose and neutrophil-to-lymphocyte ratio for differentiating CT-positive from CT-negative mild traumatic brain injury.","authors":"Marios Lampros, George A Alexiou, Solonas Symeou, Lamprini Vlachodimitropoulou, Aikaterini Zerva, Spyridon Voulgaris","doi":"10.1080/17520363.2026.2615618","DOIUrl":"10.1080/17520363.2026.2615618","url":null,"abstract":"This study aimed to assess the diagnostic utility of routine laboratory biomarkers in adults with mTBI. We conducted a prospective study of patients who were admitted to the neurosurgical department with mTBI, had admission laboratory data available, and a brain CT scan was performed. The cohort included 101 patients (mean age: 59 ± 23.14 years). Falls were the most frequent mechanism of TBI (73.2%). Subdural hematoma (SDH) was the most frequent type of intracranial injury (31.7%), followed by contusions (28.7%), and subarachnoid hemorrhage (22.7%). Patients with intracranial trauma had higher neutrophil-to- lymphocyte (NLR) ratio (p = 0.042) and higher glucose levels (p = 0.021) than patients with concussion. Additionally, patients with SDH had significantly higher NLR and glucose levels than patients with other intracranial trauma concussion. ROC analysis showed that NLR and glucose discriminated SDH from contusion with AUCs of 0.74 (95% CI: 0.59 - 0.89) and 0.80 (95% CI: 0.7-0.9), respectively. These findings require validation in larger cohorts and suggest a meaningful role of routine biomarkers in the emergency management of mTBI. However, the single-center design and modest sample size, exclusion of patients suffering from multiple injuries, diabetes or hematologic diseases may affect measured associations.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"37-45"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12947557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145958742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel circRNA signatures in cervical cancer: implications for early detection and screening. 宫颈癌中新的环状rna特征：对早期检测和筛查的意义。

IF 2.1 4区医学

Biomarkers in medicine Pub Date : 2026-01-01 Epub Date: 2026-02-19 DOI: 10.1080/17520363.2026.2631965

Michael Zhong, Josephine Peitz, Michelle Newman, Samiatu Yussuf, Clement A Adebamowo, Kiranpreet K Chawla, Diana N Carvajal, Amy J Plotkin, Paul N Staats, Sally N Adebamowo

{"title":"Novel circRNA signatures in cervical cancer: implications for early detection and screening.","authors":"Michael Zhong, Josephine Peitz, Michelle Newman, Samiatu Yussuf, Clement A Adebamowo, Kiranpreet K Chawla, Diana N Carvajal, Amy J Plotkin, Paul N Staats, Sally N Adebamowo","doi":"10.1080/17520363.2026.2631965","DOIUrl":"10.1080/17520363.2026.2631965","url":null,"abstract":"Introduction: Circular RNAs (circRNAs) are emerging as potential biomarkers due to their role in gene regulation. We explored whether specific circRNAs could serve as biomarkers for cervical cancer screening by distinguishing between different stages of cervical disease.Areas covered: We analyzed circRNA expression from archival formalin-fixed paraffin-embedded cervical tissues obtained from 272 women, of which 36% were benign, 33% were precancerous and 31% were cancerous. We performed differential expression analysis using DESeq2 to identify circRNAs that showed log2 fold change ≥2.Expert opinion/commentary: We identified 5790 statistically significant circRNAs that were differentially expressed between benign and cancerous cervical tissues; circ_0123115 (log2FC = 5.10, p = 1.66 × 10-55), associated with FGF12, was the most significant. Comparing benign to precancerous tissues, we found 1439 circRNAs with statistically significant differential expression, with circ_0100775 (log2FC = 2.13, p = 1.38 × 10-18), associated with TDRD3, being the most significant. Between precancerous and cancerous tissues, 4915 circRNAs were differentially expressed with statistical significance; circ_0006038 (log2FC = 4.74, p = 1.22 × 10-40), associated with STXBP6, was the most significant. In a three-way comparison, 57,749 circRNAs were differentially expressed, with circ_0106394 (p = 3.02 × 10-21), associated with USP22, being the most significant. Our study identified circRNAs with significant differential expression across benign, precancerous, and cancerous cervical tissues, demonstrating their potential role in cervical cancer progression.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"119-128"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12947582/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146225592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stage-specific association of urinary C-megalin with diabetic kidney disease: a cross-sectional study in type 2 diabetes. 尿c - meggalin与糖尿病肾病的分期特异性关联：2型糖尿病的横断面研究

IF 2.1 4区医学

Biomarkers in medicine Pub Date : 2026-01-01 Epub Date: 2025-12-29 DOI: 10.1080/17520363.2025.2608945

Sagar Dholariya, Gyanendra Singh, Mehul Kaliya, Ragini Singh, Amit Sonagra, Deepak Parchwani

{"title":"Stage-specific association of urinary C-megalin with diabetic kidney disease: a cross-sectional study in type 2 diabetes.","authors":"Sagar Dholariya, Gyanendra Singh, Mehul Kaliya, Ragini Singh, Amit Sonagra, Deepak Parchwani","doi":"10.1080/17520363.2025.2608945","DOIUrl":"10.1080/17520363.2025.2608945","url":null,"abstract":"Aims: This study aimed to evaluate urinary C-megalin in relation to disease staging and diagnostic accuracy in Indian patients with type 2 diabetes mellitus (T2DM).Materials and methods: In this cross-sectional study, 325 participants were classified into No-DKD, early-DKD, and late-DKD based on kidney disease improving global outcomes (KDIGO) criteria. Urinary C-megalin was quantified by enzyme-linked immunosorbent assay (ELISA) as absolute and creatinine-normalized values. Group comparisons, correlation analyses, and multinomial logistic regression were performed to assess associations with disease stage.Results: Creatinine-normalized C-megalin excretion was higher in early-DKD compared with No-DKD (median 125.0 vs. 92.0 ng/mg Cr; p = 0.02) and independently associated with early disease [odds ratio (OR) = 1.26, 95% confidence interval (CI): 1.03-1.55; p = 0.02). In late-DKD, absolute C-megalin levels were significantly associated with disease status (OR = 1.23, 95% CI: 1.02-1.48; p = 0.03), while normalized values lost significance. Diagnostic evaluation showed moderate accuracy for detecting early-DKD [area under curve (AUC): 0.69, 95% CI: 0.62-0.76, p = 0.001).Conclusion: Urinary C-megalin demonstrates stage-dependent diagnostic behavior in DKD, suggesting potential as a complementary marker for early tubular injury and advanced disease in high-risk diabetic populations.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"5-15"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12947567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145848873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revolutionizing breast cancer healthcare: the latest innovations in diagnostic biomarkers. 革新乳腺癌医疗保健：诊断生物标志物的最新创新。

IF 2.1 4区医学

Biomarkers in medicine Pub Date : 2026-01-01 Epub Date: 2026-02-23 DOI: 10.1080/17520363.2026.2634443

Saeeda Tariq, Samia Afzal

引用次数: 0

Prognostic value of the CALLY index in predicting mortality in patients with infective endocarditis. CALLY指数预测感染性心内膜炎患者死亡率的预后价值。

IF 2.1 4区医学

Biomarkers in medicine Pub Date : 2026-01-01 Epub Date: 2026-02-12 DOI: 10.1080/17520363.2026.2630028

Huseyin Orta, Cihan Aydin, Aykut Demirkiran, Zarifa Orta

{"title":"Prognostic value of the CALLY index in predicting mortality in patients with infective endocarditis.","authors":"Huseyin Orta, Cihan Aydin, Aykut Demirkiran, Zarifa Orta","doi":"10.1080/17520363.2026.2630028","DOIUrl":"10.1080/17520363.2026.2630028","url":null,"abstract":"Objectives: This study aimed to investigate the predictive value of the C-reactive protein-albumin-lymphocyte (CALLY) index for mortality in patients diagnosed with Infective Endocarditis (IE).Methods: We retrospectively analyzed 100 patients diagnosed with IE based on Duke criteria between 2016 and 2024. The CALLY index was calculated at admission using the formula: [(albumin × lymphocyte count)/CRP]. Demographic, clinical, laboratory, and echocardiographic data were collected.Results: Mortality occurred in 55% of patients. The deceased group had significantly lower CALLY index values compared to survivors (median: 1.7 vs. 6.9, p < 0.001). Multivariate analysis identified male sex (OR 3.791, p = 0.043), diabetes mellitus (OR 4.126, p = 0.022), and a lower CALLY index (OR 0.824, p = 0.005) as independent predictors of mortality, with lower CALLY values being associated with a higher risk of death. The CALLY index demonstrated moderate discriminative power (AUC = 0.792) with a cutoff value of 3.3, which yielded 68.9% sensitivity and 69.1% specificity.Conclusions: The CALLY index, an accessible and cost-effective biomarker, is independently associated with mortality and may serve as a hypothesis-generating tool for risk stratification in IE patients. Its incorporation into routine clinical assessment may enhance early risk stratification and guide management strategies.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"87-94"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12947561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of PRKAA2 and LKB1 genetic variants on metabolic alterations in response to metformin-sulfonylurea therapy. PRKAA2和LKB1基因变异对二甲双胍-磺酰脲治疗后代谢改变的影响

IF 2.1 4区医学

Biomarkers in medicine Pub Date : 2026-01-01 Epub Date: 2025-12-30 DOI: 10.1080/17520363.2025.2608954

Aliya Abbas Rizvi, Mohammad Abbas, Asma Imran Ansari, Sushma Verma, Zeba Siddiqi, Farzana Mahdi

{"title":"Impact of PRKAA2 and LKB1 genetic variants on metabolic alterations in response to metformin-sulfonylurea therapy.","authors":"Aliya Abbas Rizvi, Mohammad Abbas, Asma Imran Ansari, Sushma Verma, Zeba Siddiqi, Farzana Mahdi","doi":"10.1080/17520363.2025.2608954","DOIUrl":"10.1080/17520363.2025.2608954","url":null,"abstract":"Background: Metformin-sulfonylurea combination is a widely prescribed as second-line therapy for type 2 diabetes mellitus (T2DM), yet patient responses vary due to individual genetic variation. These variations, particularly in AMP-activated protein kinase (AMPK) and its upstream regulator liver kinase B1 (LKB1), may contribute to differences in treatment response. This study investigated the association of PRKAA2(rs2746338) and LKB1(rs741765) polymorphisms with metformin-sulfonylurea response in T2DM patients.Methods: We enrolled 193 T2DM patients on metformin-sulfonylurea therapy after obtaining written consent. Glycemic and lipid parameters were assessed at baseline and after 3 months. Genotyping was performed by PCR-RFLP and ARMS-PCR for PRKAA2(rs2746338) and LKB1(rs741765), respectively. Statistical analysis was conducted using SPSS v27.Results: Genotype and allele distributions were not significantly different between responders and non-responders. Carriers of PRKAA2(rs2746338) AA and AG and LKB1(rs741765) CT genotypes showed greater FBG reduction (p = 0.028, p < 0.001, and p < 0.001 respectively). Additionally, PRKAA2(rs2746338) AG and LKB1(rs741765) CT genotypes showed significant improvements in PPG, HbA1c, triglycerides, and LDL (all p < 0.05).Conclusion: We conclude that PRKAA2(rs2746338) and LKB1(rs741765) variants were linked to favorable glycemic and lipid changes, suggesting reduced cardiovascular risk in T2DM. These variants may serve as pharmacogenetic markers for personalized therapy, warranting validation in larger studies.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"27-35"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12947565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145854399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contemporary perspective and practical application of glutamate dehydrogenase in nonclinical studies. 谷氨酸脱氢酶在非临床研究中的当代观点和实际应用。

IF 2.1 4区医学

Biomarkers in medicine Pub Date : 2025-12-01 DOI: 10.1080/17520363.2025.2595911

Ravindra C Kodihalli, Mehrdad Ameri, Kevin S Baker, Samantha C Faber, Armando R Irizarry Rovira, Jonathan P Jackson, Leah M Norona, William R Proctor, Jessica M Caverly Rae, Arie Regev, Melanie Z Sakatis, Dominic P Williams, Doris Zane, Payal Rana

{"title":"Contemporary perspective and practical application of glutamate dehydrogenase in nonclinical studies.","authors":"Ravindra C Kodihalli, Mehrdad Ameri, Kevin S Baker, Samantha C Faber, Armando R Irizarry Rovira, Jonathan P Jackson, Leah M Norona, William R Proctor, Jessica M Caverly Rae, Arie Regev, Melanie Z Sakatis, Dominic P Williams, Doris Zane, Payal Rana","doi":"10.1080/17520363.2025.2595911","DOIUrl":"10.1080/17520363.2025.2595911","url":null,"abstract":"The use of biomarkers in nonclinical species has gained significant attention for improving predictive accuracy in toxicological studies and early disease detection. This article focuses on glutamate dehydrogenase (GLDH), a mitochondrial enzyme currently under regulatory review for qualification as a clinical biomarker to detect hepatocellular injury in patients with elevated serum transaminases due to muscle injury. GLDH has shown effectiveness in evaluating liver injury, particularly in rodents and non-human primates. This opinion paper outlines the potential of GLDH as a biomarker for monitoring drug-induced liver injury (DILI), drawing on the expertise of authors from the IQ DILI Initiative. It highlights industry consensus on GLDH use in nonclinical studies and its relevance in toxicology and drug development. The advantages and challenges of GLDH are discussed, including its interpretation as a mechanistic biomarker with translational relevance. Recent advancements in GLDH research in nonclinical species with different disease backgrounds and therapeutic modalities are explored. The integration of GLDH with other biomarkers to enhance the overall assessment of nonclinical species is reviewed. Our collective consensus opinion on GLDH is that it may offer an additional benefit over traditional biomarkers for hepatotoxicity, particularly when test articles cause increased serum transaminases due to concurrent muscle injury.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1181-1187"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12758256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145653286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of a novel diagnostic model integrating microRNAs and GALAD for HBV-related hepatocellular carcinoma. 整合microrna和GALAD的新型hbv相关肝细胞癌诊断模型的建立

IF 2.1 4区医学

Biomarkers in medicine Pub Date : 2025-12-01 Epub Date: 2025-12-11 DOI: 10.1080/17520363.2025.2600248

Yihui Yang, Anli Jin, Yan Zhou, Wenhao Wu, Chunyan Zhang, Baishen Pan, Beili Wang, Yunfan Sun, Wei Guo

{"title":"Development of a novel diagnostic model integrating microRNAs and GALAD for HBV-related hepatocellular carcinoma.","authors":"Yihui Yang, Anli Jin, Yan Zhou, Wenhao Wu, Chunyan Zhang, Baishen Pan, Beili Wang, Yunfan Sun, Wei Guo","doi":"10.1080/17520363.2025.2600248","DOIUrl":"10.1080/17520363.2025.2600248","url":null,"abstract":"Aims: As primary hepatocellular carcinoma (HCC) is a prevalent digestive tract malignancy, identifying novel biomarkers for early diagnosis and prognosis is crucial. This study combined specific miRNAs with the GALAD model to create a new diagnostic model for hepatitis B virus (HBV)-related HCC.Patients & methods: From 2020 to 2022, 884 patients from Zhongshan Hospital were enrolled, including 430 HBV-related HCC, 275 HBV-related chronic liver disease (CLD), and 179 healthy donors (HD). Stepwise regression selected features, and multivariable logistic regression built the GALADM model. A nomogram integrating age, gender, serum markers, and a score derived from seven plasma cell-free microRNAs (miRNA7) was developed.Results: MiRNA7 value was higher in HCC patients and rose with disease progression. The GALADM model showed superior diagnostic performance, with AUCs of 0.87, 0.96, and 0.90 when distinguishing HCC from CLD, HD, and CLD+HD, outperforming the GALAD model and single markers. It also excelled in diagnosing early-stage and Alpha-fetoprotein (AFP)-negative HCC. The nomogram had an AUC of 0.977 and proved clinically useful.Conclusion: The GALADM model, combining miRNA7 with the GALAD model, surpasses the original GALAD model, enabling early-stage and AFP-negative HCC diagnosis.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1255-1265"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12758346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145721074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatic steatosis/fibrosis related biomarkers in patients with metabolic dysfunction-associated steatotic liver disease. 代谢功能障碍相关脂肪性肝病患者的肝脂肪变性/纤维化相关生物标志物

IF 2.1 4区医学

Biomarkers in medicine Pub Date : 2025-12-01 Epub Date: 2025-11-27 DOI: 10.1080/17520363.2025.2595909

Zhi Peng, Zijin Wang, Juan Wang, Xuefeng Li

{"title":"Hepatic steatosis/fibrosis related biomarkers in patients with metabolic dysfunction-associated steatotic liver disease.","authors":"Zhi Peng, Zijin Wang, Juan Wang, Xuefeng Li","doi":"10.1080/17520363.2025.2595909","DOIUrl":"10.1080/17520363.2025.2595909","url":null,"abstract":"Aims: To explore hepatic steatosis and fibrosis related biomarkers in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).Patients and methods: Total 158 patients with MASLD were tested with Fibroscan to measure hepatic steatosis value (CAP value) and liver fibrosis value (E value), and divided into mild group (31 cases), moderate (49 cases), and severe fatty liver group (78 cases) according to CAP value; no fibrosis group (106 cases), early fibrosis group (38 cases), and advanced fibrosis and cirrhosis group (14 cases) according to E value.Results: E value was negatively correlated with CHOL and LDL, and CAP value was positively correlated with LDL. TG, CHOL and LDL levels in severe fatty liver group were significantly higher than those in mild fatty liver group; TG and LDL levels in moderate fatty liver group were higher than those in mild fatty liver group. TG level in early fibrosis group was significantly higher than that in advanced fibrosis and cirrhosis group.Conclusion: With the aggravation of hyperlipidemia, hepatic steatosis increases; with the aggravation of liver fibrosis, TG level decreases. Lipid metabolism worsens with the degree of steatosis. LDL is related to the severity of hepatic steatosis and fibrosis.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1239-1243"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12758338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145630048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combined predictive value of serum endothelin-1 and fibroblast growth factor-23 for in-stent restenosis following vertebral artery stenting: a novel biomarker strategy. 血清内皮素-1和成纤维细胞生长因子-23对椎动脉支架内再狭窄的联合预测价值：一种新的生物标志物策略。

IF 2.1 4区医学

Biomarkers in medicine Pub Date : 2025-12-01 Epub Date: 2025-12-10 DOI: 10.1080/17520363.2025.2600707

Yanxuan Hu, Cong Wu, Chunli Wu, Yuan Liu, Changyang Zhong

{"title":"Combined predictive value of serum endothelin-1 and fibroblast growth factor-23 for in-stent restenosis following vertebral artery stenting: a novel biomarker strategy.","authors":"Yanxuan Hu, Cong Wu, Chunli Wu, Yuan Liu, Changyang Zhong","doi":"10.1080/17520363.2025.2600707","DOIUrl":"10.1080/17520363.2025.2600707","url":null,"abstract":"Purpose: In-stent restenosis (ISR) after vertebral artery stenting (VAS) affects 20-35% of patients, yet current risk stratification lacks sensitivity for early intervention. We propose the first combined biomarker model integrating endothelin-1 (ET-1) and fibroblast growth factor 23 (FGF23) to address this gap.Methods: A prospective cohort study was conducted involving 148 patients who underwent VAS between 2020 and 2024. Blood samples were collected preoperatively to measure ET-1 and FGF23 levels. ISR was defined as a stenosis of at least 50% on follow-up imaging. Statistical analyses included multivariable logistic regression and receiver operating characteristic (ROC) curve evaluations to assess the biomarkers' performance.Results: ISR occurred in 34 patients (23%). Both ET-1 and FGF23 levels were significantly higher in the ISR group. Multivariate analysis identified ET-1, FGF23, stent length, and LDL-C levels as independent predictors of ISR. The combined model using both biomarkers demonstrated superior discriminative performance (AUC = 0.96) compared to individual markers (AUC = 0.73 for ET-1 and AUC = 0.77 for FGF23). The model achieved sensitivity and specificity of 92.3% and 89.7%, respectively.Conclusion: The combined assessment of serum ET-1 and FGF23 exhibits a synergistic predictive role for ISR after VAS. The ET-1/FGF23 model enables personalized risk stratification, guiding targeted therapies to reduce recurrent ischemic events and healthcare costs.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1247-1253"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12758235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145713322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0